These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17342690)

  • 1. [Hemolytic uremic syndrome].
    Mele C; Noris M
    G Ital Nefrol; 2007; 24(1):23-33. PubMed ID: 17342690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hemolytic uremic syndrome].
    Rota S; Cravedi P; Remuzzi G; Ruggenenti P
    G Ital Nefrol; 2005; 22 Suppl 33():S57-64. PubMed ID: 16419008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome.
    Polito MG; Kirsztajn GM
    J Bras Nefrol; 2010; 32(3):303-15. PubMed ID: 21103695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background.
    Bresin E; Daina E; Noris M; Castelletti F; Stefanov R; Hill P; Goodship TH; Remuzzi G;
    Clin J Am Soc Nephrol; 2006 Jan; 1(1):88-99. PubMed ID: 17699195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical hemolytic uremic syndrome: update on the complement system and what is new.
    Hirt-Minkowski P; Dickenmann M; Schifferli JA
    Nephron Clin Pract; 2010; 114(4):c219-35. PubMed ID: 20090363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence of hemolytic uremic syndrome after renal transplantation.
    Seitz B; Albano L; Vocila F; Mzoughi S; Aoudia R; Guitard J; Ribes D; Vachet-Copponat H; Mourad G; Bienaimé F; Dahan P; Frémeaux-Bacchi V; Cassuto E
    Transplant Proc; 2007 Oct; 39(8):2583-5. PubMed ID: 17954182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome.
    Richards A; Kathryn Liszewski M; Kavanagh D; Fang CJ; Moulton E; Fremeaux-Bacchi V; Remuzzi G; Noris M; Goodship TH; Atkinson JP
    Mol Immunol; 2007 Jan; 44(1-3):111-22. PubMed ID: 16882452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.
    Sellier-Leclerc AL; Fremeaux-Bacchi V; Dragon-Durey MA; Macher MA; Niaudet P; Guest G; Boudailliez B; Bouissou F; Deschenes G; Gie S; Tsimaratos M; Fischbach M; Morin D; Nivet H; Alberti C; Loirat C;
    J Am Soc Nephrol; 2007 Aug; 18(8):2392-400. PubMed ID: 17599974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome.
    Fremeaux-Bacchi V; Moulton EA; Kavanagh D; Dragon-Durey MA; Blouin J; Caudy A; Arzouk N; Cleper R; Francois M; Guest G; Pourrat J; Seligman R; Fridman WH; Loirat C; Atkinson JP
    J Am Soc Nephrol; 2006 Jul; 17(7):2017-25. PubMed ID: 16762990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation.
    Kavanagh D; Burgess R; Spitzer D; Richards A; Diaz-Torres ML; Goodship JA; Hourcade DE; Atkinson JP; Goodship TH
    Mol Immunol; 2007 May; 44(12):3162-7. PubMed ID: 17368771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.
    Saunders RE; Abarrategui-Garrido C; Frémeaux-Bacchi V; Goicoechea de Jorge E; Goodship TH; López Trascasa M; Noris M; Ponce Castro IM; Remuzzi G; Rodríguez de Córdoba S; Sánchez-Corral P; Skerka C; Zipfel PF; Perkins SJ
    Hum Mutat; 2007 Mar; 28(3):222-34. PubMed ID: 17089378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemolytic uremic syndrome recurrence after renal transplantation.
    Loirat C; Fremeaux-Bacchi V
    Pediatr Transplant; 2008 Sep; 12(6):619-29. PubMed ID: 18482212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A favorable 3-year outcome of kidney transplantation in atypical hemolytic uremic syndrome associated with a factor H mutation: case report.
    Albertazzi V; Bonucchi D; De Amicis S; Americo C; Ghiandai G; Cappelli G
    Transplant Proc; 2010 May; 42(4):1352-4. PubMed ID: 20534299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation.
    Ferraris JR; Ramirez JA; Ruiz S; Caletti MG; Vallejo G; Piantanida JJ; Araujo JL; Sojo ET
    Pediatr Nephrol; 2002 Oct; 17(10):809-14. PubMed ID: 12376808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical haemolytic uraemic syndrome.
    Kavanagh D; Goodship TH; Richards A
    Br Med Bull; 2006; 77-78():5-22. PubMed ID: 16968692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts.
    Fremeaux-Bacchi V; Kemp EJ; Goodship JA; Dragon-Durey MA; Strain L; Loirat C; Deng HW; Goodship TH
    J Med Genet; 2005 Nov; 42(11):852-6. PubMed ID: 15784724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of defective complement control in hemolytic uremic syndrome.
    Zipfel PF; Misselwitz J; Licht C; Skerka C
    Semin Thromb Hemost; 2006 Mar; 32(2):146-54. PubMed ID: 16575689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemolytic uremic syndrome: an example of insufficient complement regulation on self-tissue.
    Atkinson JP; Liszewski MK; Richards A; Kavanagh D; Moulton EA
    Ann N Y Acad Sci; 2005 Nov; 1056():144-52. PubMed ID: 16387683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hemolytic uremic syndrome in adults].
    Hertig A; Ridel C; Rondeau E
    Nephrol Ther; 2010 Jul; 6(4):258-71. PubMed ID: 20399168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
    Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
    J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.